Cencora (COR), despite encountering roadblocks, has seen notable moves recently. While potentially rewarding, ambiguous valuations and data breach risks raise concerns. Over the past months, various holdings such as
Kathmere Capital Management LLC and
Baker Ellis Asset Management LLC have increased their shares in Cencora, perhaps in line with its strong healthcare sector outperformance. However, unexpected downturns also occurred, attributed to reasons such as Walgreens closures. Notwithstanding, COR stock grew 19% in Q1 and 13.2% YTD, alongside received an 'Outperform' rating from
SVB Leerink. Despite insider sales from executives like
Steven Collis, the company recorded an impressive rise with its share price crossing a 200-day moving average, suggesting a long-term bullish trend for the firm. Nevertheless, a cybersecurity attack has triggered concern over the safety of Americans' health data. Amidst these diverse influences, Cencora reaffirmed its financial outlook for 2024 and announced CEO changes, a move that has seemingly prompted solid returns for its investors.
Cencora COR News Analytics from Thu, 09 Nov 2023 08:00:00 GMT to Sun, 30 Jun 2024 17:40:48 GMT -
Rating 1
- Innovation 8
- Information 7
- Rumor -4
